Patent application number | Description | Published |
20100093812 | DESFERRITHIOCIN POLYETHER ANALOGUES - A relatively non-toxic desazadesferrithiocin analog having the formula (I): wherein: R | 04-15-2010 |
20120184586 | DESFERRITHIOCIN POLYETHER ANALOGUES AND USES THEREOF - Desferrithiocin analogues represents by the structural formulae described here, such as formula (I), are useful in treating conditions such as metal overload (e.g., iron overload from transfusion therapy), oxidative stress, and neoplastic and preneoplastic conditions. | 07-19-2012 |
20130030028 | DESFERRITHIOCIN POLYETHER ANALOGUES - Compounds represented by structural formulas described herein, such as Structural Formula (I): | 01-31-2013 |
20130210870 | DESFERRITHIOCIN POLYETHER ANALOGUES - A relatively non-toxic desazadesferrithiocin analog having the formula: | 08-15-2013 |
20140235680 | DESFERRITHIOCIN POLYETHER ANALOGUES - Compounds represented by structural formulas described herein, such as Structural Formula (I): | 08-21-2014 |
20140323534 | USES OF 3'-DESFERRITHIOCIN ANALOGS - Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a polyether moiety at the 3′-position of the phenyl ring of the compound. Formula (I). | 10-30-2014 |
20140343110 | USES OF 4'-DESFERRITHIOCIN ANALOGS - Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a polyether moiety at the 4′-position of the phenyl ring of the compound. | 11-20-2014 |
20150071961 | SIDEROPHORE CONJUGATE IMMUNOGENIC COMPOSITIONS AND VACCINES - An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immunologic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine. | 03-12-2015 |